Clobazam Use in Epilepsia Partialis Continua - Pilot Study

• Sponsor: The Cooper Health System (Other)
• Overall Status: Terminated
• CT.gov ID: NCT02134366
• Collaborator: Lundbeck LLC (Industry)
• Enrollment: 7
• Location: 1
• Arms: 3
• Duration (Months): 36
• Patients Per Site Per Month: 0.2

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate whether clobazam, brand name Onf®, is more effective as an adjunctive or monotherapy in terminating Epilepsia Partialis Continua (EPC) than either lorazepam and/or clonazepam.

Condition or Disease	Intervention/Treatment	Phase
Epilepsia Partialis Continua; Kojewnikov's Epilepsy; Epilepsy	Drug: Clobazam; Drug: Clonazepam; Drug: Lorazepam	Phase 3

Detailed Description

First approved in the United States in 2011 for use in treating Lennox-Gastaut syndrome, clobazam is the only 1, 5-benzodiazepine that is currently approved for clinical use in the United States. In previous clinical trials clobazam has been shown to have a greater efficacy and produce fewer side effects in individuals when it's adverse event profile is compared to the traditional 1,4-benzodiazepines such as diazepam, lorazepam, and clonazepam. As a benzodiazepine, clobazam has been found to have anticonvulsant properties, and structural differences as a 1,5-benzodiazepines that appear to have a broader spectrum of anticonvulsant activity than those found in 1,4-benzodiazepines. In previous reports, clobazam has been seen to be effective in ether terminating or reducing both EPC in particular and partial status epilepticus.

Study Design

• Study Type: Interventional
• Actual Enrollment: 7 participants
• Allocation: Randomized
• Intervention Model: Factorial Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase III, Randomized, Open Label, Single Center, Study on the Effects of Treatment of Epilepsia Partialis Continua With Clobazam Compared to Treatment With or in Addition to Lorazepam and/or Clonazepam
• Study Start Date: Jul 1, 2014
• Actual Primary Completion Date: Jul 1, 2017
• Actual Study Completion Date: Jul 1, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Clobazam Subjects who are assigned the clobazam treatment group will receive a 10mg loading dose followed by a maintenance dose of 5-25 mg bid starting 12 hrs after the loading dose. If subjects are found to have failed to respond to treatment with clobazam, the physician investigator has the ability to either start another AED or increase the dose of clobazam depending on the clinical situation. Subjects still being treated with clobazam at discharge will be given a 30 day supply of clobazam.	Drug: Clobazam; Comparison of AED use in Epilepsia Partialis Continua; Other Names: Onfi Frisium Urbanol ; Drug: Clonazepam; Comparison of AED use in Epilepsia Partialis Continua; Other Names: Klonopin ; Drug: Lorazepam; Comparison of AED use in Epilepsia Partialis Continua; Other Names: Ativan Orfidal
Active Comparator: Clonazepam Subjects who are assigned to the clonazepam treatment group will receive a dose of 1-2mg clonazepam dose tid. Following the initial treatment if a physician investigator determines that the subject's treatment has failed, the investigator has the option of treating the subject with clobazam at which point the individuals would be treated in the same method as those originally assigned to the clobazam treatment group.	Drug: Clobazam; Comparison of AED use in Epilepsia Partialis Continua; Other Names: Onfi Frisium Urbanol ; Drug: Clonazepam; Comparison of AED use in Epilepsia Partialis Continua; Other Names: Klonopin ; Drug: Lorazepam; Comparison of AED use in Epilepsia Partialis Continua; Other Names: Ativan Orfidal
Active Comparator: Lorazepam Subjects who are assigned to the lorazepam treatment group will receive a 1-2mg dose of lorazepam qid. Following the initial treatment if a physician investigator determines that the subject's treatment has failed, the investigator has the option of treating the subject with clobazam at which point the individuals would be treated in the same method as those originally assigned to the clobazam treatment group.	Drug: Clobazam; Comparison of AED use in Epilepsia Partialis Continua; Other Names: Onfi Frisium Urbanol ; Drug: Clonazepam; Comparison of AED use in Epilepsia Partialis Continua; Other Names: Klonopin ; Drug: Lorazepam; Comparison of AED use in Epilepsia Partialis Continua; Other Names: Ativan Orfidal

Outcome Measures

Primary Outcome Measures

1. Time (measured in minutes) to onset of seizure freedom [Within 7 days]

2. Reduction of seizure frequency/minute [Within 7 days]

Secondary Outcome Measures

1. Mental status preservation off sedating anticonvulsants as measured by the MoCA© scale [Within 37 days]

2. Ambulatory function as measured by the Hauser Ambulation Index [Within 37 days]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

•≥ to 18 yrs of age

•Diagnosis of EPC by a Neurologist

Exclusion Criteria:

• Previous exposure to clobazam prior to presentation

• Seizure generalization

• Patients who are intubated and on IV sedation such as Versed®, Propofol or Presedex®.

• Female subjects who are pregnant and/or breast-feeding

• Subject has an unstable and/or serious or psychiatric illness

• Subject has an unstable and/or serious medical illness

• Subject has any of the following but not limited to conditions:

• A life threatening medical condition

• Severe sepsis or septic shock

• Severe Renal impairment

• Severe Hepatic impairment

• Sleep apnea

• Narrow angle glaucoma

• Severe respiratory insufficiency

• Myasthenia gravis

• Metastatic cancer

• Organ failure

• Severe progressive nervous system disease

• A clinically significant EKG abnormality that would be affected by and/or affect the patient's participation in the trial

• Subject has active suicidal ideation at Screening and Baseline visits

• Subject has a history of suicidal thoughts or behaviors, which would be indicated by a positive response to questions 4 and/or 5 on the CSSR-S. Exclusionary actions include but are not limited to:

• Previous intent to act on suicidal ideation with a specific plan

• Previous preparatory acts or behavior

• A previous actual attempt, interrupted attempt or aborted suicide attempt

• Subject has a history of alcohol and/or substance abuse in the previous 12 months, or the subject is unable to refrain from alcohol and/or substance abuse during the study.

• Subject admits to present illicit drug use or has a positive drug screen

• Subject is currently enrolled in or has been enrolled in any clinical trial within the past 30 days

• Subject has a known allergy to any component of the study medication(s)

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Cooper Universtiy Hospital	Camden	New Jersey	United States	08103

Sponsors and Collaborators

• The Cooper Health System
• Lundbeck LLC

Investigators

• Principal Investigator: Melissa Carran, MD, Cooper University Health System

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: The Cooper Health System
• ClinicalTrials.gov Identifier: NCT02134366
• Other Study ID Numbers: EPC-1
• First Posted: May 9, 2014
• Last Update Posted: May 9, 2018
• Last Verified: May 1, 2018

• Keywords provided by The Cooper Health System: Epilepsia Partialis Continua; Kojewnikov's Epilepsy; Epilepsy; Clobazam; Focal Motor Epilepsy; Partial Motor Seizure
• Additional relevant MeSH terms: Epilepsy; Epilepsia Partialis Continua; Lorazepam; Clonazepam; Clobazam

Study Results

No Results Posted as of May 9, 2018